Many tumor‐associated antigens (TAAs) recognized by cytotoxic T cells (CTLs) have been
identified during the last two decades and some of them have been used in clinical trials …

Host antitumor immune responses may be different between hepatocellular carcinoma
(HCC) caused by metabolic disorders and HCC associated with hepatitis virus infection. In …

Background & Aims Levels of α-fetoprotein (AFP) are measured for surveillance and
diagnosis of hepatocellular carcinoma (HCC). We performed a phase 1 trial to evaluate the …

Hepatocellular carcinoma (HCC) is a deadly cancer with a 5-year survival of 18% for
patients at all stages.(1) Systemic treatments for advanced-stage HCC, including targeted …

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide with
limited therapeutic options. Since HCC has been shown to be immunogenic, T cell-based …

Aim We investigated whether tumor-specific CD8+ T-cell responses affect tumor-free
survival as well as the relationship between CD8+ T-cell responses against tumor …

Background: The distinct expression pattern of tumour-associated antigens (TAAs) might be
a critical reason for the inefficacy of immunity-based treatments and heterogeneous …

Abstract α‐Fetoprotein (AFP) has been proposed as a potential target forT‐cell‐based
immunotherapy for hepatocellular carcinoma (HCC), but the number of its epitopes that have …

Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide with a poor
prognosis and limited therapeutic options. To aid the development of novel immunological …

Introduction: Immunotherapy is on the way to become the new standard of care for advanced
hepatocellular carcinoma (HCC) worldwide. With higher rates of objective responses, and …